Irish Journal of Medical Science

, Volume 180, Issue 2, pp 355–362 | Cite as

Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care

  • A. Jan
  • N. F. Murphy
  • C. O’Loughlin
  • M. Ledwidge
  • K. McDonaldEmail author
Original Article



To examine the prognostic importance of absolute values and change in values of BNP in patients with stable heart failure (HF).


Five-hundred and fifty-nine patients attending a disease management programme were categorized into tertiles of BNP (group 1; ≤95 pg/ml, group 2; 96–249 pg/ml and group 3; ≥250 pg/ml). A change in BNP between two stable visits was recorded. Patients were followed up for 1 year for death and a composite morbidity measure of HF hospitalization, all-cause hospitalization, unscheduled visits for clinical deterioration(UC) of HF using survival analysis.


The risk of the combined morbidity outcome increased with increasing tertiles of BNP (Log rank = 17.8 (2), p < 0.001). Furthermore, a 50 and 25% increase in BNP predicted morbidity in stable HF patients with an initial BNP > 200 pg/ml (p = 0.02) and >450 pg/ml (p = 0.03), respectively.


In a stable community HF population, an elevated BNP or an increase in BNP predicts an adverse prognosis thereby potentially identifying a population in need of closer clinical follow-up.


B-type natriuretic peptide Heart failure Disease management programme 


Conflicts of interest

KMCD and ML have received honoraria from Biosyn. There are no other conflicts of interest.


  1. 1.
    Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMedCrossRefGoogle Scholar
  2. 2.
    Logeart D, Thabut G, Jourdain P et al (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43:635–641PubMedCrossRefGoogle Scholar
  3. 3.
    Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:1943–1950PubMedCrossRefGoogle Scholar
  4. 4.
    Yu CM, Sanderson JE (1999) Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1:59–65PubMedCrossRefGoogle Scholar
  5. 5.
    Ishii J, Nomura M, Nakamura Y et al (2002) Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89:691–695PubMedCrossRefGoogle Scholar
  6. 6.
    Cournot M, Leprince P, Destrac S, Ferrieres J (2007) Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am J Geriatr Cardiol 16:8–14PubMedCrossRefGoogle Scholar
  7. 7.
    Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W (2001) Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38:1934–1941PubMedCrossRefGoogle Scholar
  8. 8.
    de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C (2004) B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43:1584–1589PubMedCrossRefGoogle Scholar
  9. 9.
    Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625PubMedCrossRefGoogle Scholar
  10. 10.
    Jourdain P, Jondeau G, Funck F et al (2007) Plasma brain natriuretic peptide guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739PubMedCrossRefGoogle Scholar
  11. 11.
    Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRefGoogle Scholar
  12. 12.
    Castellanos LR, Bhalla V, Isakson S, et al (2008) B-type Natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events. J Card Fail (article in press)Google Scholar
  13. 13.
    O’Hanlon R, O’Shea P, Ledwidge M et al (2007) The biologic variability of B type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13:50–55PubMedCrossRefGoogle Scholar
  14. 14.
    Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR (2007) Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9:68–74PubMedCrossRefGoogle Scholar
  15. 15.
    Moertl D, Berger R, Hammer A et al (2009) B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure. J Card Fail 15:233–240PubMedCrossRefGoogle Scholar
  16. 16.
    Wei T, Zeng C, Chen L et al (2005) Systolic and diastolic heart failure are associated with different plasma levels of B-type natriuretic peptide. Int J Clin Pract 59:891–894PubMedCrossRefGoogle Scholar
  17. 17.
    McDonald K, Ledwidge M, Cahill J et al (2002) Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. J Card Fail 8:142–148PubMedCrossRefGoogle Scholar
  18. 18.
    Ledwidge M, Ryan E, O’Loughlin C et al (2005) Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. Eur J Heart Fail 7:385–391PubMedCrossRefGoogle Scholar
  19. 19.
    Nieminen MS, Böhm M, Cowie MR et al (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26:384–416Google Scholar
  20. 20.
    Cheng V, Kazanagra R, Garcia A et al (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386–391PubMedCrossRefGoogle Scholar
  21. 21.
    Hosmer D, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. John Wiley & Sons, Inc, New YorkGoogle Scholar
  22. 22.
    Maeda K, Tsutamoto T, Wada A et al (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587–1593PubMedCrossRefGoogle Scholar
  23. 23.
    Rienstra M, Van GI, Van den Berg MP, Boomsma F, van Veldhuisen DJ (2006) Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-) ANP and (NT-pro) BNP. Europace 8:482–487PubMedCrossRefGoogle Scholar
  24. 24.
    Watanabe J, Shiba N, Shinozaki T et al (2005) Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail 11:50–55PubMedCrossRefGoogle Scholar
  25. 25.
    Berger R, Huelsman M, Strecker K et al (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105:2392–2397PubMedCrossRefGoogle Scholar
  26. 26.
    Valle R, Aspromonte N, Feola M et al (2005) B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 11:498–503PubMedCrossRefGoogle Scholar
  27. 27.
    Aspromonte N, Feola M, Milli M et al (2007) Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Diabet Med 24:124–130PubMedCrossRefGoogle Scholar
  28. 28.
    Verdiani V, Nozzoli C, Bacci F et al (2005) Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 7:566–571PubMedCrossRefGoogle Scholar
  29. 29.
    Christ M, Laule-Kilian K, Hochholzer W et al (2006) Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 48:1808–1812PubMedCrossRefGoogle Scholar
  30. 30.
    Harrison A, Morrison LK, Krishnaswamy P et al (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39:131–138PubMedCrossRefGoogle Scholar
  31. 31.
    Anand IS, Fisher LD, Chiang YT et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMedCrossRefGoogle Scholar
  32. 32.
    Wijeysundera HC, Hansen MS, Stanton E et al (2003) Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J 146:291–297PubMedCrossRefGoogle Scholar
  33. 33.
    Ryder M, Murphy NF, McCaffrey D, O’Loughlin C, Ledwidge M, McDonald K (2008) Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail 10:267–272PubMedCrossRefGoogle Scholar
  34. 34.
    Conlon C, O’Loughlin C, Ledwidge M, McDonald K (2006) Community Direct Access Service for Early Detection and Treatment of Clinical Deterioration: Effectiveness and Impact on the Workload Pattern of a Hospital-Based Heart Failure Unit. Dis Manage Health Outcomes 14:185–190CrossRefGoogle Scholar
  35. 35.
    Miller WL, Hartman KA, Burritt MF et al (2007) Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 116:249–257PubMedCrossRefGoogle Scholar
  36. 36.
    Bettencourt P, Frioes F, Azevedo A et al (2004) Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93:45–48PubMedCrossRefGoogle Scholar
  37. 37.
    Masson S, Latini R, Anand IS et al (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003PubMedCrossRefGoogle Scholar
  38. 38.
    Maeder MT, Hack D, Rickli H et al (2008) Relevance of short-term variation of B-type natriuretic peptide in patients with clinically stable heart failure. Wien Klin Wochenschr 120:672–678PubMedCrossRefGoogle Scholar
  39. 39.
    Pfisterer M, Buser P, Rickli H et al (2009) BNP-Guided vs Symptom-Guided Heart Failure Therapy The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial. JAMA 301:383–392PubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2011

Authors and Affiliations

  • A. Jan
    • 1
  • N. F. Murphy
    • 1
  • C. O’Loughlin
    • 1
  • M. Ledwidge
    • 1
  • K. McDonald
    • 1
    Email author
  1. 1.Department of Cardiology, Heart Failure UnitSt. Vincent’s University Hospital and University College DublinDublin 4Ireland

Personalised recommendations